Liliana Elena Weimer | Medicine and Health Sciences | Best Researcher Award

Published on by Top Teachers

Best Researcher Award

Liliana Elena Weimer
Italian National Institute of Health, Italy
Liliana Elena Weimer
Affiliation Italian National Institute of Health
Country Italy
Google Scholar 2q3g0CAAAAAJ
Documents 128
Citations 2,534
h-index 22
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
Scopus ID 6701388312
ORCID 0000-0002-1554-3150

Liliana Elena Weimer is a medical doctor and clinical researcher with over 30 years of experience in infectious diseases, clinical trials, and global health. Since 2022 she serves as First Researcher (Level II) at the Center for Global Health – Istituto Superiore di Sanità (ISS), Rome, Italy. Her career spans landmark HIV/HCV studies, COVID‑19 surveillance, Long‑COVID coordination, and international collaborations with WHO, the G20, and the American Clinical Trials Group.[1][2]

She has participated in national and multinational cohort studies, public health surveillance programs, and clinical research initiatives focused on infectious diseases and global health. As of September 2026, she has authored or co-authored more than 177 scientific publications and has contributed to research programs involving the American Clinical Trials Group, European collaborative projects, WHO-related activities, and Italian national surveillance systems. Her scholarly profile reflects sustained engagement in evidence-based medicine, public health research, and clinical investigation across several decades.[1][2]

Abstract

This article presents the academic and research profile of Dr. Liliana Elena Weimer, nominated for the Best Researcher Award in recognition of her outstanding contributions to clinical virology, public health surveillance, and international collaborative research. With a career spanning more than three decades at the Italian National Institute of Health (ISS), Dr. Weimer has coordinated national and multinational trials on HIV and HCV, contributed to the PITER cohort (25,000 patients), and led COVID‑19 and Long‑COVID surveillance protocols. Her work is characterised by high‑impact publications, a consistent h‑index of 22, and active engagement in European projects (ORCHESTRA, PREVENT Horizon, SHIELD). The nomination is supported by her record of public competition successes, teaching, and service with Doctors Without Borders.[1]

Keywords

Best Researcher Award, HIV/HCV clinical trials, PITER cohort, COVID‑19 surveillance, Long‑COVID, Malattie Infettive Long Covid, Doctor in Medicine, Infectious Diseases.

Introduction

The Best Researcher Award recognises individuals who demonstrate exceptional scientific output, leadership, and translational impact. Liliana Elena Weimer, MD, has built a distinguished career at the Istituto Superiore di Sanità (ISS), where she has been instrumental in shaping infectious disease research in Italy and beyond. Her work encompasses antiretroviral therapy optimisation, hepatitis C elimination strategies, and the establishment of national surveillance systems for HIV, HCV, and SARS‑CoV‑2. Notably, she is a member of the ISS COVID‑19 National Surveillance Group and the PITER study coordination team, and she contributes to WHO guidelines on Long‑Covid. Her international collaborations and sustained publication record make her a strong candidate for this award.[3]

Research Profile

Dr. Liliana Elena Weimer holds a medical degree from the University of Buenos Aires and a second MD from the University of L’Aquila, with specialisations in Infectious Diseases and Clinical Pharmacology. She has been a researcher at ISS since 1990, winning public competitions for fixed‑term, permanent, and First Researcher positions. Her research profile is characterised by a strong commitment to clinical epidemiology and trial methodology. She has contributed to landmark studies such as ACTG 384/388 (Italy‑USA AIDS trials), the PITER HCV cohort, and the European ORCHESTRA project. She also coordinates the national Long‑COVID surveillance protocol (2021‑2026) funded by the Italian Ministry of Health. With over 128 documents, 2,534 citations, and an h‑index of 22 (Scopus), she maintains a visible presence in the field.[2][4]

  • Senior Clinical Researcher at the Italian National Institute of Health (ISS), Rome.
  • More than three decades of experience in multicenter clinical trials and epidemiological research.
  • Collaborator with international HIV and HCV research networks.
  • Contributor to national SARS-CoV-2 and Long COVID surveillance programs.
  • Participant in European collaborative projects including ORCHESTRA, PREVENT Horizon, SHIELD, EURO-PERISTAT, and JA-05.
  • Member of professional organizations focused on infectious diseases and public health.

Research Contributions

Dr. Liliana Elena Weimer’s contributions are organised around three pillars: clinical trials and cohort studies, public health surveillance, and global health collaborations. She has coordinated over twenty national and international multicentre trials, including the Italian Protease Inhibitors Registry and the NIA surveillance network. As part of the PITER study, she contributed to the largest Italian HCV cohort (25,000 patients), informing treatment strategies for cirrhosis and hepatocellular carcinoma. During the COVID‑19 pandemic, she joined the ISS national surveillance group and collaborated with Bambino Gesù Pediatric Hospital, providing clinical and epidemiological support. She also serves as an external consultant for WHO’s Long‑Covid guidelines and is a member of the Brussels Network of Expertise on Long‑Covid.[5]

Liliana Elena Weimer’s research portfolio encompasses HIV treatment optimization, hepatitis C management, SARS-CoV-2 surveillance, and Long COVID characterization. Her participation in national cohort studies and international clinical trials has contributed to understanding treatment effectiveness, patient outcomes, and disease epidemiology.[1][3]

  • Clinical trials and cohort studies involving HIV therapies.
  • Research on HCV treatment outcomes and long-term virological response.
  • Investigation of monoclonal antibody strategies against emerging SARS-CoV-2 variants.
  • Long COVID symptom characterization and longitudinal follow-up studies.
  • Public health surveillance and antimicrobial resistance research.
  • Support for healthcare access initiatives in resource-limited settings.

Publications

Dr. Liliana Elena Weimer has authored or co‑authored more than 120 peer‑reviewed articles, book chapters, and monographs. Her work appears in high‑impact journals including Hepatology, Children, and Journal of Pediatrics Research Reviews. She received the Best Research Award from the journal Children (IF 2.5) for a study on the clinical characterisation of adolescents with Long‑COVID. She has also published two books on post‑COVID sequelae and SARS‑CoV‑2 variants. Below is a selection of her most cited works:

  • Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, … Weimer LE (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3):833‑844.
  • George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, … Weimer LE (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3):729‑738.
  • Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, … Weimer LE (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3):715‑725.

Research Impact

With over 2,534 citations and an h‑index of 22, Dr. Liliana Elena Weimer’s work has shaped clinical practice in hepatitis C and HIV care. Her studies on sustained virologic response and long‑term outcomes after HCV therapy are frequently cited in guidelines. She has received multiple recognitions, including an Abstract of Distinction at the AASLD Liver Meeting (2018) and the 2025 Best Research Award from Children journal. She was a Special Invitee to the G20 Health Summit 2023 and serves as a lay judge at the Court of Assizes in Rome. Her impact extends beyond academia: she is a volunteer with Doctors Without Borders (since 1992), providing AIDS therapies in Brazil, and actively participates in public health emergency responses.[1][3]

Award Suitability

The Best Researcher Award recognises sustained excellence, and Dr. Liliana Elena Weimer’s trajectory exemplifies this. She has won three public competitions at the ISS (fixed‑term, permanent, and First Researcher), demonstrating peer‑reviewed career progression. She coordinates the national PITER HCV cohort and the Long‑COVID surveillance protocol, and she has contributed to WHO guidelines. Her publication record includes landmark articles in hepatology, and she has received journal‑level awards for her work on Long‑COVID. Her international collaborations with the American Clinical Trials Group, INSERM, and the European Commission place her among the leading clinical researchers in Italy. This award would further acknowledge her role in translating research into public health action.[4]

Conclusion

Dr. Liliana Elena Weimer is a medical researcher of high calibre, with a career that bridges clinical trials, epidemiological surveillance, and global health equity. Her work on HIV, HCV, and COVID‑19 has informed national and international guidelines, and her commitment to service—through Doctors Without Borders and public health emergencies—distinguishes her as a compassionate and effective leader. The data presented—128 documents, 2,534 citations, h‑index 22, and consistent recognition—support her nomination for the Best Researcher Award. Her profile aligns with the core values of the award: scientific rigor, translational impact, and dedication to improving human health.[5]

References

  1. Scopus. (n.d.). Author details: Weimer, Liliana Elena, Author ID 6701388312. Scopus Preview.https://www.scopus.com/pages/authors/6701388312
  2. Google Scholar. (n.d.). Liliana Elena Weimer – citations & h‑index. Google Scholar.https://scholar.google.co.uk/citations?user=2q3g0CAAAAAJ
  3. Morgan, T. R., Ghany, M. G., Kim, H. Y., Snow, K. K., Shiffman, M. L., De Santo, J. L., … & Weimer, L. E. (2010). Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology, 52(3), 833‑844. https://doi.org/10.1002/hep.23744
  4. George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J., … & Weimer, L. E. (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‑year follow‑up of 150 patients. Hepatology, 49(3), 729‑738. https://doi.org/10.1002/hep.22694
  5. Saxena, V., Nyberg, L., Pauly, M., Dasgupta, A., Nyberg, A., Piasecki, B., … & Weimer, L. E. (2015). Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis. Hepatology, 62(3), 715‑725. https://doi.org/10.1002/hep.27922

Alessandro Orlando | Medicine and Health Sciences | Best Researcher Award

Published on by Top Teachers

Best Researcher Award

Alessandro Orlando
Center for Trauma and Acute Care Surgery Research, HCA Healthcare,  United States
Alessandro Orlando
Affiliation Center for Trauma and Acute Care Surgery Research, HCA Healthcare
Country United States
Scopus ID 48861826200
Documents 50
Citations 548
h-index 14
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
Google Scholar ZGMH340AAAAJ

Alessandro Orlando is a clinical epidemiologist, research leader, educator, and healthcare scientist affiliated with HCA Healthcare in the United States. His work focuses on clinical epidemiology, trauma research, evidence-based medicine, predictive modeling, traumatic brain injury outcomes, and translational healthcare research. Over a professional career spanning more than sixteen years, Orlando has contributed to multicenter clinical investigations, epidemiologic methodology, trauma system research, and healthcare quality improvement initiatives. His scholarly output and leadership activities have supported the advancement of trauma care and clinical decision-making in diverse healthcare settings.[1]

Abstract

This article presents a scholarly overview of Alessandro Orlando’s academic background, professional achievements, research contributions, teaching activities, and scientific impact within medicine and health sciences. His work integrates epidemiological methods, trauma outcomes research, multicenter clinical investigations, and predictive analytics to improve patient care and healthcare decision-making. Through leadership positions in trauma research organizations and HCA Healthcare, he has contributed to the development of collaborative research infrastructures and evidence-based clinical practices.[1]

Keywords

Clinical Epidemiology; Trauma Research; Evidence-Based Medicine; Health Outcomes; Predictive Modeling; Machine Learning; Traumatic Brain Injury; Multicenter Studies; Population Health; Healthcare Research Leadership.

Introduction

Alessandro Orlando is recognized for his contributions to clinical epidemiology and trauma research. His academic preparation includes a PhD in Clinical Epidemiology from Johns Hopkins University, a Master of Public Health in Epidemiology from Virginia Commonwealth University, and a Bachelor of Science in Biology. His research career has been characterized by a sustained commitment to improving healthcare outcomes through rigorous methodological approaches, multicenter collaborations, and translational clinical investigations.[1]

His work has spanned trauma systems, neurosurgical outcomes, epidemiologic study design, healthcare analytics, and the implementation of evidence-based research frameworks within complex healthcare organizations. These activities have positioned him as a contributor to both academic and applied clinical research environments.[2]

Research Profile

As Assistant Vice President at the HCA Healthcare Center for Trauma and Acute Care Surgery Research, Orlando directs research strategy, project implementation, and multidisciplinary collaboration. His responsibilities include oversight of multicenter trauma studies, management of research portfolios, and coordination of scientific dissemination activities. He has contributed to increased scholarly productivity through abstracts, manuscripts, conference presentations, and multicenter investigations involving trauma centers across the United States.[1]

  • Clinical epidemiology and outcomes research.
  • Traumatic brain injury and neurosurgical decision support.
  • Clinical prediction model development and validation.
  • Application of machine learning in healthcare.
  • Multicenter trauma and acute care surgery research.
  • Research transparency and clinical data integrity.

Research Contributions

Orlando’s research portfolio demonstrates contributions to pulmonary complications, trauma systems, neurosurgical outcomes, emergency care pathways, and clinical intervention assessment. He has participated in large multicenter observational and interventional studies that have informed clinical practice and healthcare delivery. His work frequently emphasizes methodological rigor, real-world clinical applicability, and patient-centered outcomes.[2]

In addition to publication activities, Orlando has contributed to the development of research infrastructure through management of clinical databases and implementation of standardized systems for research governance and project oversight. Such initiatives support reproducibility, transparency, and operational efficiency in clinical research programs.[1]

Publications

Among Alessandro Orlando’s most influential publications are the multicenter POPULAR study on post-anaesthesia pulmonary complications, a randomized tramadol efficacy trial, and investigations of traumatic brain injury management and thrombectomy protocols, collectively contributing to evidence-based clinical practice and patient outcomes.[2][3][4][5]

Selected publications associated with Alessandro Orlando include highly cited contributions in respiratory medicine, urology, neurosurgery, and neurointerventional science.[2][3]

  1. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study, The Lancet Respiratory Medicine, 2019.
  2. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet, European Urology, 2012.
  3. Outcomes of a nontransfer protocol for mild traumatic brain injury with abnormal head computed tomography in a rural hospital setting, World Neurosurgery, 2014.
  4. A standardized neurointerventional thrombectomy protocol leads to faster recanalization times, Journal of NeuroInterventional Surgery, 2017.

Research Impact

The documented Scopus profile indicates a publication record of 50 indexed documents, 548 citations, and an h-index of 14, reflecting measurable influence within the biomedical research community.[1]

Beyond publication metrics, Orlando’s impact is reflected through mentoring activities, graduate-level teaching appointments at Johns Hopkins University, invited lectures on epidemiologic methods, and peer-review service for scientific journals including Frontiers in Neurology and Neurotrauma Reports. These activities contribute to the dissemination of methodological expertise and the advancement of clinical research standards.[4]

Award Suitability

Alessandro Orlando’s profile demonstrates several characteristics commonly associated with academic recognition in research excellence programs. These include sustained scholarly productivity, leadership of multicenter clinical investigations, development of research infrastructure, competitive academic funding support, peer-review service, graduate-level teaching experience, and contributions to evidence-based medicine.[1]

His integration of epidemiologic science with trauma care research, together with his commitment to collaborative healthcare innovation, aligns with the objectives of professional awards that recognize impactful research, educational contributions, and advancement of healthcare knowledge.[2]

Conclusion

Alessandro Orlando has established a multidisciplinary career at the intersection of clinical epidemiology, trauma research, and healthcare innovation. His contributions encompass scientific publication, research leadership, education, peer review, and multicenter collaboration. The available evidence indicates a sustained commitment to improving patient outcomes through evidence-based methodologies and clinically relevant research initiatives. Collectively, these accomplishments provide a substantive basis for consideration within professional research recognition programs such as the Best Researcher Award.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Alessandro Orlando, Author ID 48861826200. Scopus. https://www.scopus.com/pages/authors/48861826200
  2. Kirmeier, E., Eriksson, L. I., Lewald, H., Fagerlund, M. J., Hoeft, A., Hollmann, M., et al. (2019). Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. The Lancet Respiratory Medicine, 7(2), 129–140. DOI: https://doi.org/10.1016/S2213-2600(18)30294-7
  3. Bar-Or, D., Salottolo, K. M., Orlando, A., Winkler, J. V., et al. (2012). A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of acute pain. European Urology, 61(4), 736–743. DOI: https://doi.org/10.1016/j.eururo.2011.08.039
  4. Levy, A. S., Orlando, A., Salottolo, K., Mains, C. W., & Bar-Or, D. (2014). Outcomes of a nontransfer protocol for mild traumatic brain injury with abnormal head computed tomography in a rural hospital setting. World Neurosurgery, 82(1–2), e319–e323. DOI: https://doi.org/10.1016/j.wneu.2013.11.008
  5. Frei, D., McGraw, C., McCarthy, K., Whaley, M., Bellon, R. J., Loy, D., Wagner, J., et al. (2017). A standardized neurointerventional thrombectomy protocol leads to faster recanalization times. Journal of NeuroInterventional Surgery, 9(11), 1035–1040. DOI: https://doi.org/10.1136/neurintsurg-2016-012716

Timea Claudia Ghitea | Medicine and Health Sciences | Women Researcher Award

Published on by Top Teachers

Women Researcher Award

Timea Claudia Ghitea
University of Oradea, Romania
Timea Claudia Ghitea
Affiliation University of Oradea
Country Romania
Scopus ID 57214826600
Documents 103
Citations 722
h-index 15
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
ORCID 0000-0001-8981-1958
Google Scholar VsFBqbQAAAAJ

Timea Claudia Ghitea is a Romanian academic, pharmacist, nutrition specialist, and university educator affiliated with the Faculty of Medicine and Pharmacy at the University of Oradea. Her scholarly activities integrate clinical nutrition, metabolic disorders, dietetics, rehabilitation medicine, pharmaceutical sciences, and public health research. Through academic teaching, clinical practice, and scientific publication, she has contributed to advancing evidence-based nutritional interventions and multidisciplinary healthcare approaches. Her research profile demonstrates sustained engagement in metabolic syndrome, diabetes, probiotics, sarcopenia, rehabilitation outcomes, and maternal health studies.[1][2]

Abstract

This article summarizes the academic achievements, professional experience, research output, and scientific impact of Timea Claudia Ghitea. Her work spans medicine, pharmacy, nutrition science, and metabolic health, with particular emphasis on evidence-based dietary interventions and patient-centered healthcare. Through extensive publication activity and interdisciplinary collaboration, she has contributed to contemporary understanding of chronic disease management, rehabilitation nutrition, and probiotic-based therapeutic approaches.[1]

Keywords

Clinical Nutrition, Dietetics, Metabolic Syndrome, Diabetes Mellitus, Probiotics, Sarcopenia, Rehabilitation Medicine, Pharmacy, Biomedical Sciences, Public Health, Farmacie, Nutriție, Stiinte Biomedicale, Microbiommi, Microbiologie, General & Internal Medicine, Research & Experimental Medicine, Biochemistry & Molecular Biology, Health Care Sciences & Services, Nutrition & Dietetics.

Introduction

Timea Claudia Ghitea has developed a multidisciplinary career combining pharmaceutical practice, academic instruction, nutrition consultancy, and biomedical research. Since 2017 she has served as University Assistant at the Faculty of Medicine and Pharmacy, University of Oradea, while simultaneously practicing as a clinical and sports nutritionist. Her educational background includes degrees in biology, chemistry, pharmacy, cell biology, and a PhD in Biomedical Sciences with specialization in clinical and sports nutrition, providing a comprehensive foundation for translational healthcare research.[1]

Research Profile

The research profile of Timea Claudia Ghitea reflects sustained scholarly productivity in medicine and health sciences, supported by more than one hundred indexed publications, substantial citation activity, and an established h-index. Her investigations focus on nutrition-related interventions, metabolic disorders, gastrointestinal microbiota, pharmaceutical sciences, rehabilitation outcomes, and clinical management strategies for chronic diseases. The interdisciplinary nature of her work facilitates collaboration among physicians, pharmacists, nutritionists, and public health researchers.[1][2]

Research Contributions

  • Advanced understanding of probiotic and prebiotic applications in metabolic syndrome and type 2 diabetes management.[3]
  • Contributed to evidence regarding nutritional therapy for sarcopenia associated with immobilization and chronic disease conditions.[6]
  • Investigated dietary intervention strategies influencing sarcopenic indicators among patients with metabolic syndrome.[7]
  • Supported multidisciplinary studies examining rehabilitation outcomes and prevention of secondary complications following spinal cord injury.[5]
  • Participated in comprehensive reviews addressing maternal health and antiphospholipid syndrome during pregnancy.[4]

Publications

Notable publications include research on gut microbiota and metabolic disease, pregnancy-related autoimmune disorders, rehabilitation medicine, nutrition-based interventions for sarcopenia, and metabolic syndrome management. These studies collectively demonstrate a commitment to translational healthcare research with practical clinical applications.[3][4][5][6][7]

  1. Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium.
  2. Antiphospholipid Syndrome in Pregnancy: A Comprehensive Literature Review.
  3. The Outcomes of Robotic Rehabilitation Assisted Devices Following Spinal Cord Injury and the Prevention of Secondary Associated Complications.
  4. The Contribution of Diet Therapy and Probiotics in the Treatment of Sarcopenia Induced by Prolonged Immobilization Caused by the COVID-19 Pandemic.
  5. The Influence of Diet Therapeutic Intervention on the Sarcopenic Index of Patients with Metabolic Syndrome.

Research Impact

With 103 indexed documents, 722 citations, and an h-index of 15, Timea Claudia Ghitea has established a measurable academic presence within medicine and health sciences. Her publications have contributed to contemporary discussions regarding nutrition-based therapeutic approaches, metabolic disease management, rehabilitation medicine, and clinical healthcare optimization. The citation performance of her work indicates ongoing scholarly engagement and relevance within multiple biomedical disciplines.[1]

Award Suitability

Timea Claudia Ghitea demonstrates several characteristics commonly associated with recognition through a Women Researcher Award. These include sustained publication productivity, interdisciplinary scientific contributions, active involvement in academic teaching, leadership in healthcare practice, mentorship activities, professional society memberships, and research addressing significant public health challenges. Her integration of clinical practice and academic scholarship illustrates a model of translational research with practical societal relevance.[1][2]

Conclusion

Timea Claudia Ghitea has built a distinguished academic and professional career spanning pharmacy, nutrition, medicine, and health sciences. Her research contributions, publication record, educational achievements, and clinical expertise collectively demonstrate a sustained commitment to advancing evidence-based healthcare. These accomplishments support her profile as a noteworthy contributor to biomedical research and higher education.

References

  1. Elsevier. (n.d.). Scopus author details: Timea Claudia Ghitea, Author ID 57214826600. Scopus. https://www.scopus.com/authid/detail.uri?authorId=57214826600
  2. ORCID. (n.d.). Timea Claudia Ghitea researcher profile. https://orcid.org/0000-0001-8981-1958
  3. TC Ghitea et al. Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium. Microorganisms. https://doi.org/10.3390/microorganisms9030618
  4. TC Ghitea et al. Antiphospholipid Syndrome in Pregnancy: A Comprehensive Literature Review. BMC Pregnancy and Childbirth. https://link.springer.com/article/10.1186/s12884-025-07471-w
  5. TC Ghitea et al. The Outcomes of Robotic Rehabilitation Assisted Devices Following Spinal Cord Injury and the Prevention of Secondary Associated Complications. Medicina. https://doi.org/10.3390/medicina58101447
  6. TC Ghitea et al. The Contribution of Diet Therapy and Probiotics in the Treatment of Sarcopenia Induced by Prolonged Immobilization Caused by the COVID-19 Pandemic. Nutrients. https://doi.org/10.3390/nu14214701
  7. Ghitea TC et al. The influence of diet therapeutic intervention on the sarcopenic index of patients with metabolic syndrome. Acta Endocrinologica. https://pmc.ncbi.nlm.nih.gov/articles/PMC8126402/

Song Guo Zheng | Medicine and Health Sciences | Best Innovator Award

Published on by Top Teachers

Best Innovator Award

Song Guo Zheng
Shanghai Jiao Tong University, China
Song Guo Zheng
Affiliation Shanghai Jiao Tong University
Country China
Scopus ID 7403146499
Documents 262
Citations 16,675
h-index 75
Subject Area Medicine and Health Sciences
Event Top Teachers Awards
ORCID 0000-0002-5611-4774
Google Scholar 37kvQ18AAAAJ

Song Guo Zheng is a physician-scientist and immunologist whose academic career has spanned molecular immunology, rheumatology, autoimmunity, cell therapy, and translational medicine. His research has contributed to the understanding of regulatory T cells, immune tolerance, autoimmune disease mechanisms, and therapeutic immunomodulation. He currently serves as Chair Professor of Medicine and Dean of the School of Cell and Gene Therapy at Shanghai Jiao Tong University School of Medicine while maintaining extensive leadership roles in international scientific organizations and scholarly publishing.[1]

Abstract

This article evaluates the academic achievements, scientific leadership, educational service, and innovation record of Song Guo Zheng in relation to the Best Innovator Award. His work integrates fundamental immunology with translational medicine, resulting in influential publications, patents, edited books, international collaborations, and leadership positions across major scientific societies. The breadth of his contributions demonstrates sustained impact on biomedical research and clinical immunology.[1]

Keywords

Rheumatology, Immunology, Autoimmunity, T Regulatory Cells, Cell Therapy, GMSC, Tumor Immunity.

Introduction

Over several decades, Song Guo Zheng has established an interdisciplinary research program focused on immune regulation, autoimmune disease pathogenesis, regenerative medicine, and therapeutic cell engineering. His academic development includes medical training in China, doctoral education in France, and faculty appointments at major institutions in the United States and China. His scientific output has contributed to both theoretical and applied aspects of immunological science.[1]

Research Profile

Song Guo Zheng earned an M.D. from Anhui Medical University and later completed a Ph.D. in Molecular Immunology at the University of Orleans, France. His academic appointments have included leadership roles at the University of Southern California, Penn State University, Ohio State University, and Shanghai Jiao Tong University. He has also served as editor, associate editor, and editorial board member for numerous high-impact journals while participating in major international grant-review panels and scientific committees.[1]

Research Contributions

  • Advanced understanding of regulatory T-cell biology and immune tolerance mechanisms.[2]
  • Developed strategies for immune modulation relevant to autoimmune disorders and inflammatory diseases.[3]
  • Contributed to translational research in cell therapy, tumor immunity, and regenerative medicine.
  • Secured multiple granted patents involving regulatory T cells, exosome applications, and immunotherapeutic technologies.[1]
  • Edited scientific books and chapters that support education and dissemination of immunological knowledge.

Publications

Representative publications include influential studies on regulatory T-cell induction, immune tolerance, vitamin-mediated immune regulation, and chronic disease immunobiology. These works have become widely cited within immunology and rheumatology literature.[2][3][4][5][6]

Research Impact

According to the provided scholarly metrics, the researcher has produced 262 indexed documents, accumulated more than 16,675+ citations, and achieved an h-index of 75. These indicators reflect substantial scholarly visibility and influence within biomedical sciences. His leadership in international societies, conference organization, editorial service, and research mentoring further extends the impact of his work beyond publication metrics alone.[1]

Award Suitability

The Best Innovator Award recognizes individuals who demonstrate sustained innovation, measurable research impact, educational leadership, and translational achievement. Song Guo Zheng’s portfolio includes pioneering immunological discoveries, numerous patents, extensive publication activity, scientific leadership, international recognition, and contributions to medical education. These accomplishments collectively support strong consideration for recognition within innovation-focused academic award programs.[1]

Conclusion

Song Guo Zheng has developed a distinguished career characterized by innovation in immunology, leadership in academic medicine, and contributions to translational biomedical research. His scientific achievements, educational service, publication record, patents, and international professional engagement provide a substantial foundation for recognition under the Best Innovator Award framework.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Song Guo Zheng, Author ID 7403146499. Scopus. https://www.scopus.com/authid/detail.uri?authorId=7403146499
  2. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and Induced CD4+CD25+ Cells Educate CD4+CD25− Cells to Develop Suppressive Activity. The Journal of Immunology. https://doi.org/10.4049/jimmunol.172.9.5213
  3. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of Vitamin A in the Immune System. Journal of Clinical Medicine. https://doi.org/10.3390/jcm7090258
  4. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.178.4.2018
  5. Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA. Generation Ex Vivo of TGF-β-Producing Regulatory T Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.169.8.4183
  6. Wang H, Chen W, Li D, Yin X, Zhang X, Olsen N, Zheng SG. Vitamin D and Chronic Diseases. Aging and Disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC5440113/

Sebiha Demir | Health Sciences | Best Researcher Award

Published on by Top Teachers

Ms. Sebiha Demir | Health Sciences | Best Researcher Award

University Hospital Bonn | Germany

Ms. Sebiha Demir is a dedicated medical researcher specializing in neonatology, neonatal neuroprotection, and perinatal brain injury. Her research focuses on improving clinical outcomes for asphyxiated newborns through evidence-based innovations in therapeutic hypothermia and neurophysiological monitoring. She integrates advanced diagnostic tools such as amplitude-integrated electroencephalography (aEEG) and biochemical profiling to identify early predictors of hypoxic-ischemic encephalopathy (HIE), advancing precision medicine in neonatal intensive care. Her notable publication, “Abnormal Amplitude‐Integrated Electroencephalography and Acidosis as Key Criteria Initiating Therapeutic Hypothermia in Asphyxiated Newborns – Data From the German Hypothermia Registry” (Acta Paediatrica, 2025), demonstrates her significant contribution to establishing objective criteria for initiating life-saving interventions in high-risk neonates. Through collaborative research with multidisciplinary teams across Europe, Dr. Demir has enriched neonatal care protocols and contributed to shaping guidelines for early neurological assessment and treatment strategies. Her internationally recognized publications reflect a strong academic impact and translational value in pediatric and clinical neuroscience. With over 380 citations, an h-index of 10 on Scopus, and 12 on Google Scholar, her scholarly influence and commitment to impactful research are evident. As a forward-thinking clinician–scientist, she continues to advance neonatal research by integrating data-driven insights with compassionate care. Dr. Demir’s excellence, innovation, and dedication to improving neonatal health outcomes position her as a leading figure in her field and a deserving recipient of the Best Researcher Award, honoring her outstanding contributions to advancing neonatal medicine and inspiring future generations of medical scientists.

Publication Profile

Orcid

Featured Publications

Demir, S., Groteklaes, A., Dresbach, T., Müller, A., & Sabir, H. (2025, October 29). Abnormal amplitude-integrated electroencephalography and acidosis as key criteria initiating therapeutic hypothermia in asphyxiated newborns – Data from the German Hypothermia Registry. Acta Paediatrica.